Related Experiment Video

Updated: Jul 10, 2026

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

Proton pump inhibitor utilization patterns in infants

John J Barron1, Hiangkiat Tan, James Spalding

  • 1HealthCore, Inc, Wilmington, DE, USA. jbarron@healthcore.com

Journal of Pediatric Gastroenterology and Nutrition
|November 22, 2007
PubMed

Insights

Proton pump inhibitor (PPI) use in infants and neonates increased fourfold between 2000 and 2003. These findings highlight current PPI dosing patterns for pediatric gastroesophageal reflux disease, informing future clinical trials.

Area of Science:

  • Pediatric Gastroenterology
  • Neonatal Pharmacology
  • Drug Utilization Studies

Background:

  • Pediatric gastroesophageal reflux disease (GERD) management often involves acid suppression.
  • Proton pump inhibitors (PPIs) are frequently used in infants, but utilization patterns require examination.

Purpose of the Study:

  • To investigate the utilization patterns of proton pump inhibitors (PPIs) in infants and neonates.
  • To assess demographic information and PPI dosing in a pediatric population.

Main Methods:

  • Retrospective observational study using data from 1999-2004 across four US healthcare plans.
  • Identified infants (<12 months) with at least one PPI pharmacy claim.
  • Assessed demographic data, PPI utilization, and dosing via chart review in a subset.

Main Results:

  • PPI use increased fourfold from 2000-2003, with lansoprazole and omeprazole being predominant.
  • Commonly associated diagnoses included gastroesophageal reflux, feeding problems, and upper respiratory infections.
  • Longer PPI duration correlated with increased comorbidities; median daily dosages were established for lansoprazole and omeprazole.

Conclusions:

  • PPI utilization in infants and neonates showed a steady increase from 1999 to 2004.
  • The study provides crucial data on PPI dosing patterns in infants.
  • Findings can inform the design of future clinical trials for pediatric GERD.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...